Ticker > Company >

Emami share price

Emami Ltd.

  3.04 L   1.29 K   150 NSE: EMAMILTD BSE: 531162 SECTOR: Household & Personal Products

401.65
-3.20 (-0.79%)
BSE: 18 Aug 04:01 PM

Price Summary

Today's High

₹ 406.95

Today's Low

₹ 397.6

52 Week High

₹ 634.65

52 Week Low

₹ 376.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

17532.02 Cr.

Enterprise Value

17290.02 Cr.

No. of Shares

43.65 Cr.

P/E

20.37

P/B

5.25

Face Value

₹ 1

Div. Yield

2.49 %

Book Value (TTM)

₹  76.47

CASH

317 Cr.

DEBT

75 Cr.

Promoter Holding

54.84 %

EPS (TTM)

₹  19.72

Sales Growth

-2.41%

ROE

27.95 %

ROCE

29.61%

Profit Growth

-2.05 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Emami Ltd.

Dermicool BORO PLUS Navratna ZANDU BALM FAIR AND HANDSOME MENTHO PLUS BALM FAST RELIEF SONA CHANDI Chyawanprash Plus Kesari Jivan Vasocare ZANDU 7 OILS IN ONE Kesh King DIAMOND SHINE HE GOLDEN BEAUTY Talc Naturally Fair GLOW AND HANDSOME

Index Presence

The company is present in 28Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-2.41%
3 Year1.6%
5 Year3.37%

Profit Growth

1 Year-2.05%
3 Year13.64%
5 Year12.11%

ROE%

1 Year27.95%
3 Year30.17%
5 Year32.23%

ROCE %

1 Year29.61%
3 Year32.44%
5 Year31.55%

Debt/Equity

0.0238

Price to Cash Flow

22.07

Interest Cover Ratio

459.5563

CFO/PAT (5 Yr. Avg.)

0.975434506211063

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 54.84 16.23
Mar 2026 54.84 16.43
Dec 2025 54.84 11.60
Sep 2025 54.84 9.98
Jun 2025 54.84 10.50
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 30.1742666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 32.4425% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 459.5563.
  • The Company has been maintaining an effective average operating margins of 29.6748004241874% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -51.2388 days.
  • Company has a healthy liquidity position with current ratio of 3.0106.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 16.6441558338196.

 Limitations

  • The company has shown a poor revenue growth of 1.5962403694362% for the Past 3 years.
  • Tax rate is low at 6.5683.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 756.46 604.47 957.72 729.61 779.92
Total Expenditure 555.89 436.85 572.42 533.11 564.48
Operating Profit 200.57 167.62 385.3 196.5 215.44
Other Income 20.91 53.85 19.21 24.57 53.18
Interest 0.5 0.47 0.49 0.5 0.89
Depreciation 39.45 40.15 40.09 35.94 34.13
Exceptional Items 0 0 -10.15 0 0
Profit Before Tax 181.53 180.85 353.78 184.63 233.6
Tax 18.44 -1.49 23.98 18.24 51.38
Profit After Tax 163.09 182.34 329.8 166.39 182.22
Adjusted EPS (Rs) 3.74 4.18 7.56 3.81 4.17

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 2866.87 2906.83 2921.57 3123.55 3048.26
Total Expenditure 1969.69 2129.39 2069.58 2186.27 2098.27
Operating Profit 897.19 777.44 851.99 937.28 949.99
Other Income 122.94 48 69.24 157.44 118.54
Interest 3.45 3.73 2.12 2.11 1.96
Depreciation 327.61 215.38 166.57 158.38 155.63
Exceptional Items 0 0 -5.9 0 -10.15
Profit Before Tax 689.06 606.33 746.64 934.22 900.79
Tax -161.61 32.83 53.26 75.02 59.17
Net Profit 850.68 573.5 693.39 859.2 841.62
Adjusted EPS (Rs.) 19.28 13 15.89 19.68 19.28

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 44.12 44.12 43.65 43.65 43.65
Total Reserves 2041.84 2219.58 2339.32 2823.51 3111.97
Borrowings 0 0 0 0 0
Other N/C liabilities -233.8 -311.57 -396.25 -483.03 -579.14
Current liabilities 690.02 437.6 424.43 479.38 526.86
Total Liabilities 2542.18 2389.73 2411.16 2863.51 3103.34
Assets
Net Block 1225.87 1044.9 917.65 799.28 708.08
Capital WIP 1.28 1.13 4.58 11.15 0.79
Intangible WIP 1.35 0.57 0.61 1.32 0.58
Investments 321.34 278.19 398.68 571.47 723.69
Loans & Advances 24.09 20.68 13.74 33.62 39.71
Other N/C Assets 123.86 65.05 59.52 45.02 44.32
Current Assets 844.4 979.21 1016.38 1401.65 1586.16
Total Assets 2542.18 2389.73 2411.16 2863.51 3103.34
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 689.06 606.33 746.64 934.22 900.79
Adjustment 225.23 219.12 116.91 20.43 50.57
Changes in Assets & Liabilities -188.3 13.5 7 76.47 -9.56
Tax Paid -130.14 -107.99 -130.76 -167.55 -147.39
Operating Cash Flow 595.85 730.96 739.8 863.57 794.4
Investing Cash Flow -187.9 -105.59 -192.29 -464.76 -256.74
Financing Cash Flow -398.07 -612.17 -546.12 -367.88 -462.26
Net Cash Flow 9.88 13.2 1.39 30.93 75.4

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 54.84 54.84 54.84 54.84 54.84
abhishek agarwal 0.02 0.02 0.02 0.02 0.02
aditya vardhan agarwal 0.05 0.05 0.05 0.05 0.05
aditya vardhan agarwal hu... 0.05 0.05 0.05 0.05 0.05
advay goenka 0.13 0.13 0.13 0.13 0.13
amitabh goenka 0.13 0.13 0.13 0.13 0.13
amitabh goenka huf 0.02 0.02 0.02 0.02 0.02
ashish goenka 0.07 0.07 0.07 0.07 0.07
ashish goenka huf 0.02 0.02 0.02 0.02 0.02
chikky goenka 0.03 0.03 0.03 0.03 0.03
darsh goenka 0.13 0.13 0.13 0.13 0.13
devarsh goenka 0.09 0.09 0.09 0.09 0.09
divya agarwal 0.01 0.01 0.01 0.01 0.01
diwakar finvest private l... 22.63 22.63 22.63 - 22.63
emami paper mills ltd 0.21 0.21 0.21 0.21 0.21
harsha vardhan agarwal 0.05 0.05 0.05 0.05 0.05
harsha vardhan agarwal hu... 0.04 0.04 0.04 0.04 0.04
indu goenka 0.06 0.06 0.06 0.06 0.06
jayant goenka 0.04 0.04 0.04 0.04 0.04
jayant goenka huf 0.02 0.02 0.02 0.02 0.02
jyoti goenka 0.03 0.03 0.03 0.03 0.03
kusum agarwal 0.01 0.01 0.01 0.01 0.01
laxmi devi bajoria 0.02 0.02 0.02 0.02 0.02
manish goenka 0.06 0.06 0.06 0.06 0.06
manish goenka huf 0.04 0.04 0.04 0.04 0.04
mansi agarwal 0.03 0.03 0.03 0.03 0.03
mohan goenka 0.15 0.15 0.15 0.15 0.15
mohan goenka huf 0.04 0.04 0.04 0.04 0.04
nikunj goenka 0.06 0.06 0.06 0.06 0.06
pan emami cosmed limited 0.71 0.71 0.71 0.71 0.71
pradip kumar agarwal 0.01 0.01 0.01 0.01 0.01
prashant goenka 0.07 0.07 0.07 0.08 0.08
prashant goenka huf 0.02 0.02 0.02 0.02 0.02
priti a sureka 3.46 3.46 3.46 3.78 3.78
puja goenka 0.04 0.04 0.04 0.04 0.04
rachana goenka 0.03 0.03 0.03 0.03 0.03
rachna bagaria 0.06 0.06 0.06 0.06 0.06
radheshyam agarwal 0.04 0.04 0.04 0.04 0.04
radheshyam goenka 0.10 0.10 0.10 0.09 0.09
rajkumar goenka 0.15 0.15 0.15 0.27 0.27
rashmi goenka 0.06 0.06 0.06 0.06 0.06
reha goenka 0.05 0.05 0.05 0.05 0.05
reyansh goenka 0.09 0.09 0.09 0.09 0.09
richa agarwal 0.03 0.03 0.03 0.03 0.03
ritu goenka 0.10 0.10 0.10 0.10 0.10
sachin goenka 0.16 0.16 0.16 0.16 0.16
santosh goenka 0.03 0.03 0.03 0.07 0.07
saroj goenka 0.07 0.07 0.07 0.07 0.07
shobhana agarwal 0.14 0.14 0.14 0.14 0.14
smriti agarwal 0.04 0.04 0.04 0.04 0.04
suraj finvest private lim... 24.20 24.20 24.20 - 24.20
sushil kumar goenka 0.12 0.12 0.12 0.12 0.12
sushil kumar goenka huf 0.04 0.04 0.04 0.04 0.04
usha agarwal 0.20 0.20 0.20 0.20 0.20
yogesh goenka 0.06 0.06 0.06 0.06 0.06
diwakar finvest pvt ltd - - - 22.63 -
suraj finvest pvt ltd - - - 24.20 -
avishi sureka 0.32 0.32 0.32 - -
manan goenka 0.13 0.13 0.13 - -
shruti goenka 0.05 0.05 0.05 - -
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 45.16 45.16 45.16 45.16 45.16
0 - - - - 0.08
aditya birla sun life tru... - 1.29 1.33 1.33 1.16
avees trading and finance... 2.00 2.00 2.00 2.00 2.00
bandhan elss tax saver fu... - - - 1.39 1.65
dsp aggressive hybrid fun... 3.85 3.72 4.31 4.35 4.10
franklin india dividend y... - 1.69 1.61 1.87 1.84
hdfc large and mid cap fu... 3.16 3.01 3.02 3.03 3.04
investor education and pr... - - 0.13 0.13 0.13
llp - 0.05 - 0.05 0.02
nippon life india trustee... 3.28 3.59 4.79 6.09 6.64
sbi consumption opportuni... - 1.87 1.87 1.89 1.89
sundaram mutual fund a/c ... - 1.14 1.32 1.16 1.16
uti aggressive hybrid fun... 1.44 1.56 1.60 1.75 1.69
domestic corporate unclai... - - - 0.01 -
bandhan flexi cap fund - - 1.12 - -
kotak contra fund - - 2.27 - -
kotak aggressive hybrid f... - 3.37 - - -
franklin india multi cap ... 1.94 - - - -
investor education and pr... 0.10 - - - -
kotak emerging equity sch... 3.37 - - - -
sbi large & midcap fund 1.73 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research Way2wealth
Research Way 2 Wealth
Research Report By:
Research Report By:
Research Way2Wealth
Research Way2Wealth
Research Way2Wealth
Research way2wealth
Research Way2Wealth
Research Way2Wealth
Research Way2Wealth
Research Chola Wealth Direct
Research Way2Wealth
Research Chola Wealth Direct
Research Chola Wealth Direct
Research Chola Wealth Direct
Research Chola Wealth Direct
Research Chola Wealth Direct
Research Chola Wealth Direct
Research HDFC Securities
Research Nirmal Bang
Research Geojit BNP Paribas
Research HDFC Securities
Research Chola Wealth Direct

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY23
Concall Q4FY21
Concall Q4FY20
Concall Q3FY26
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY22
Concall Q1FY20
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY22
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY26
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY22
Presentation Q1FY21
Presentation Q1FY20
Presentation H1FY24
Presentation FY2023

Additional Resources & References

Company News

Emami - Quaterly Results 5 Aug, 12:00 AM Emami rises on completing acquisition of 0.31% stake in IncNut Digital 12 Jun, 2:52 PM Emami completes acquisition of 0.31% stake in IncNut Digital 12 Jun, 2:38 PM Emami informs about disclosure 9 Jun, 11:09 AM Emami completes acquisition of 59.69% stake in IncNut Digital 2 Jun, 11:29 AM Emami informs about disclosures 30 May, 11:24 AM Emami informs about newspaper publication 22 May, 4:30 PM Emami - Quaterly Results 22 May, 12:00 AM Emami informs about change in management 21 May, 3:29 PM Emami informs about press release 7 May, 4:22 PM Emami informs about acquisition 7 May, 4:16 PM Emami rises on inking pact to acquire 60% stake in IncNut Digital 7 May, 12:19 PM Emami inks pact to acquire 60% stake in IncNut Digital 7 May, 11:59 AM Emami informs about disclosures 23 Apr, 5:00 PM Emami inks pact to acquire stake in Axiom Ayurveda 2 Apr, 5:00 PM Emami - Quaterly Results 5 Feb, 12:00 AM Emami informs about disclosures 16 Jan, 11:52 AM Emami informs about board meeting 7 Jan, 5:27 PM Emami informs about closure of trading window 26 Dec, 11:57 AM Emami informs about disclosure 20 Dec, 2:36 PM Emami informs about disclosure 2 Dec, 1:01 PM Emami - Quaterly Results 11 Nov, 12:00 AM Emami informs about updates 27 Oct, 5:28 PM Emami informs about board meeting 11 Oct, 3:10 PM Emami informs about outcome of board meeting 31 Jul, 3:34 PM Emami informs about press release and investor presentation 31 Jul, 3:19 PM Emami informs about appointment of CS cum CO 31 Jul, 2:46 PM Emami - Quaterly Results 31 Jul, 1:42 PM Emami - Quaterly Results 31 Jul, 1:42 PM Emami - Quaterly Results 31 Jul, 1:42 PM Emami informs about disclosure 18 Jul, 4:56 PM Emami enters into agreement with Cannis Lupus Services India 18 Jul, 11:00 AM Emami informs about disclosure 13 Jun, 5:07 PM Emami informs about newspaper publication 9 Jun, 5:38 PM Emami informs about disclosure 3 Jun, 11:20 AM Emami informs about press release 17 May, 3:22 PM Emami - Quaterly Results 16 May, 2:20 PM Emami - Quaterly Results 16 May, 2:20 PM Emami - Quaterly Results 16 May, 2:20 PM Emami informs about disclosures 21 Mar, 4:31 PM Emami informs about disclosure 19 Feb, 5:19 PM Emami informs about disclosure 4 Feb, 12:34 PM Emami reports 7% rise in Q3 consolidated net profit 28 Jan, 12:23 PM Emami - Quaterly Results 27 Jan, 5:41 PM Emami - Quaterly Results 27 Jan, 5:41 PM Emami - Quaterly Results 27 Jan, 5:41 PM Emami informs about disclosure 24 Jan, 12:35 PM Emami informs about disclosure 21 Jan, 12:33 PM Emami planning to expand play in male grooming market 11 Jan, 2:42 PM Emami informs about outcome of board meeting 7 Nov, 5:34 PM

Emami Stock Price Analysis and Quick Research Report. Is Emami an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Emami. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Emami has a PE ratio of 20.3555889124416 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Emami has ROA of 28.21% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Emami has a Current ratio of 3.0106.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Emami has a ROE of 27.948%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Emami has a Debt to Equity ratio of 0.0238 which means that the company has low proportion of debt in its capital.

  • Sales growth: Emami has reported revenue growth of -2.4103% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Emami for the current financial year is 31.1649939367059%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Emami is Rs 10 and the yield is 2.4907%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Emami is Rs 19.7194. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Emami in Ticker for free. Also, one can get the intrinsic value of Emami by using Valuation Calculators, which are available with a Finology ONE subscription. 

Emami FAQs

Q1. What is Emami share price today?
Ans: The current share price of Emami is Rs 401.4.

Q2. What is the market capitalisation of Emami?
Ans: Emami has a market capitalisation of Rs 17521.11 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Emami?
Ans: The PE ratio of Emami is 20.3555889124416 and the P/B ratio of Emami is 5.24924086090689, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Emami share?
Ans: The 52-week high share price of Emami is Rs 634.2, and the 52-week low share price of Emami is Rs 376.4.

Q5. Does Emami pay dividends?
Ans: Currently, Emami pays dividends. Dividend yield of Emami is around 2.4907%.

Q6. What are the face value and book value of Emami shares?
Ans: The face value of Emami shares is Rs 1, while the book value per share of Emami is around Rs 76.4682. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Emami?
Ans: Emami has a total debt of Rs 75 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Emami?
Ans: The ROE of Emami is 27.948% and ROCE of Emami is 29.6078%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Emami a good buy for the long term?
Ans: The Emami long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Emami undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Emami appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Emami’s financials?
Ans: You can review Emami’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Emami

Emami: Business Overview & Financial Analysis

Emami is a prominent Indian fast-moving consumer goods (FMCG) company headquartered in Kolkata, West Bengal. Promoted by R. S. Agarwal and R. S. Goenka, the enterprise manufactures and markets a diverse portfolio of personal care, healthcare, and Ayurvedic wellness products. Operating across domestic retail, modern trade, quick-commerce, and international distribution networks, Emami manages a basket of iconic power brands including Navratna, BoroPlus, Zandu, Kesh King, Fair and Handsome (rebranded as Smart and Handsome), and Mentho Plus across 60+ countries.

Brand Portfolio & Category Volume Breakdown of Emami (FY26)

Emami structures its product lines across power brands covering healthcare, personal care, and pain management verticals.

  • Navratna Range – 28% of Total Domestic Revenue
  • BoroPlus Range – 18% of Total Domestic Revenue
  • Healthcare & Zandu Range – 18% of Total Domestic Revenue
  • Kesh King Portfolio – 12% of Total Domestic Revenue
  • Pain Management Range – 12% of Total Domestic Revenue
  • Male Grooming (Smart & Handsome) – 8% of Total Domestic Revenue
  • Other Brands & D2C Portfolio – 4% of Total Domestic Revenue

The company holds strong market leadership across niche consumer categories. Navratna maintains a dominant position in cooling oils, while BoroPlus leads the antiseptic cream segment nationwide. The Zandu healthcare portfolio anchors the Ayurvedic wellness and cough-and-cold categories.

Distribution Network & Channel Sales Mix of Emami (Q4 FY26)

Emami delivers its products through a multi-tier distribution network spanning traditional retail, organized modern trade, and quick-commerce channels.

  • Total Retail Touchpoints Footprint – 4.9 million retail outlets across India
  • Direct Retail Coverage Reach – 1.0 million retail touchpoints
  • Organized Channels Share (Modern Trade, E-Commerce, Quick-Commerce) – 32% of Domestic Revenue
  • General Trade Channel Share – 68% of Domestic Revenue
  • Quick-Commerce & E-Commerce Sales Growth – Delivered rapid double-digit expansion in Q4 FY26

Direct retail coverage reaches 1.0 million stores, backed by an overall retail footprint of 4.9 million outlets across urban and rural India. Emerging channels, particularly quick-commerce and organized marts, contribute 32% of total domestic business dispatches.

Geographic Revenue Breakdown & International Operations of Emami (FY26)

Emami balances its domestic FMCG distribution with expanding direct and indirect export dispatches.

  • Domestic Business Share – 82% of Total Operating Revenue
  • International Business Share – 18% of Total Operating Revenue
  • Primary International Geographies – SAARC, MENA (Middle East & North Africa), CIS, and South-East Asia
  • Direct Export Footprint – Operations spanning 60+ overseas countries

Domestic sales generate over four-fifths of total operating turnover, supported by extensive rural and urban coverage. The international division targets high-density South Asian diaspora regions and local healthcare markets across Middle East and CIS countries.

Manufacturing Facilities & Operations Hubs of Emami (FY26)

Emami operates state-of-the-art processing and packaging plants compliant with national and international manufacturing standards.

  • Operational Manufacturing Facilities – 9 manufacturing units across India and overseas
  • Key Domestic Plant Locations – Abhayapuri (Assam), Pantnagar (Uttarakhand), Vapi (Gujarat), Kolkata (West Bengal), Dongri (Maharashtra), and Masat (Dadra & Nagar Haveli)
  • Overseas Processing Facility – 1 manufacturing unit in Dhaka, Bangladesh
  • Regulatory Compliance Standards – WHO-GMP, ISO 9001:2015, and AYUSH-certified facilities

Manufacturing campuses in Assam and Uttarakhand handle primary high-volume production for personal care and cooling oils. Captive packaging facilities optimize unit costs and maintain strict quality standards across healthcare and skin-care product lines.

Direct-to-Consumer (D2C) Brand Investments & Subsidiaries of Emami (FY26)

Emami acquires equity stakes in fast-growing D2C personal care and male grooming brands to capture digital-first consumer segments.

  • The Man Company (Helios Lifestyle) – 100% Wholly-Owned Subsidiary (Male Grooming & Fragrances)
  • Brillare Science – Wholly-Owned Subsidiary (Professional Hair & Skin Care)
  • Cannis Oils (Axiom Ayurveda) – Strategic equity stake in 'AloFrut' fruit juice beverages
  • D2C & Strategic Subsidiaries Revenue Growth – Scaling digital-first portfolio across quick-commerce platforms

The company fully acquired Helios Lifestyle (The Man Company) to strengthen its presence in premium male grooming and digital-first channels. Strategic investments in Brillare and Axiom Ayurveda expand the addressable market across premium salon hair care and functional natural beverages.

Latest Quarterly Financial Performance of Emami (Q4 FY26)

Emami recorded resilient operating profitability despite seasonal disruptions and geopolitical headwinds in international markets.

  • Consolidated Revenue from Operations – Rs 925.00 crore (-4.0% YoY)
  • Domestic Non-Summer Portfolio Revenue Growth – +11.0% YoY
  • Consolidated Operating EBITDA – Rs 187.00 crore (-6.9% YoY)
  • Operating EBITDA Margin – 20.22%
  • Consolidated Gross Margin – 68.40% (+250 bps YoY)
  • Consolidated Net Profit After Tax (PAT) – Rs 143.00 crore (-6.0% YoY)

Fourth-quarter operating turnover stood at Rs 925.00 crore, impacted by unseasonal weather affecting the summer portfolio and shipping disruptions in West Asia. However, excluding summer brands, domestic sales grew 11%, while gross margins expanded by 250 basis points to 68.40% due to cost efficiencies.

Consolidated Annual Financial Performance of Emami (FY26)

Emami delivered full-year gross margin expansion and cash flow generation for the full financial year FY26.

  • Full Year Consolidated Revenue from Operations – Rs 3,780.00 crore (+2.5% YoY)
  • Full Year Consolidated Gross Margin – 69.90% (+130 bps YoY)
  • Full Year Consolidated Operating EBITDA – Rs 964.00 crore (+3.2% YoY)
  • Full Year Operating EBITDA Margin – 25.50% (+18 bps YoY)
  • Consolidated Net Profit After Tax (PAT) – Rs 775.00 crore (+4.8% YoY)
  • Total Dividend Declared – Rs 10.00 per equity share (51% payout ratio)

Full-year operating turnover reached Rs 3,780.00 crore in FY26, as Net Profit After Tax expanded to Rs 775.00 crore. Annual financial performance was supported by raw material price stability, disciplined cost management, and premiumisation across core categories.

Capital Structure & Balance Sheet Ratios of Emami (Q4 FY26)

Emami operates a low-debt capital structure backed by strong cash flow generation and high return metrics.

  • Debt to Equity Ratio – Net Cash Positive / Low Debt (0.02x)
  • Total Equity Base – Rs 2,922.40 crore
  • Cash, Bank Balances & Surplus Investments – Rs 680.00 crore
  • Return on Capital Employed (ROCE) – 28.5%
  • Return on Equity (ROE) – 26.2%

The company closed FY26 with Rs 680.00 crore in surplus cash reserves and a near-zero debt-to-equity ratio. High operational productivity generated a Return on Capital Employed of 28.5%, supporting an annual dividend payout of Rs 436.50 crore.

Strategic Outlook & Management Commentary of Emami (Q4 FY26)

Management guidance outlines strategic priorities centered on core volume recovery, D2C turnaround, and international market normalization.

  • Management anticipates business momentum to recover progressively, targeting high single-digit volume growth in FY27.
  • Rebranding of Fair and Handsome to 'Smart and Handsome' will expand male grooming offerings into body and hair care categories.
  • Kesh King brand restructuring and new product strategies will be executed over the next 1 to 2 quarters to restore volume growth.
  • Operating EBITDA margins are guided to sustain above 26.0%, supported by premiumisation and digital channel scaling.
  • The Man Company is projected to deliver significant operational turnaround and margin contribution starting H1 FY27.

Management expects temporary seasonal disruptions and Middle East shipping bottlenecks to normalize over upcoming quarters. Strategic focus remains on accelerating D2C brand integrations, expanding direct distribution coverage, and investing behind core power brands.

Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.

Sources & References

  1. Emami Q4 & Full Year FY26 Consolidated Financial Results Disclosures (May 2026)
  2. Emami Q4 FY26 Investor Presentation & Press Release (May 2026)
  3. National Stock Exchange of India (NSE) Corporate Filings for Emami
  4. Sharekhan Research Report on Emami
  5. Ticker Finology Emami Page

Disclaimer
The information presented above on Emami has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Emami page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Read More
X